Back to results
US 2014/0005126 A1Published application
Scaffold peptides
AssigneeIsogenica Limited
InventorsChris Ullman, Agnes Jaulent, Seema Patel, Pascale Mathonet
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeIsogenica Limited
InventorsChris Ullman, Agnes Jaulent, Seema Patel, Pascale Mathonet
Estimating the term…
A naive WW domain peptide library derived from a WW domain peptide sequence which has been diversified by changing the amino acid sequence at one or more positions is provided. The naive WW domain peptide library may be derived from a GroupIV WW domain peptide. Methods for making the naive WW domain peptide library and methods for selected a modified WW domain peptide that binds a target ligand using the naive WW domain peptide library are also provided. Also disclosed are modified WW domain peptides that bind desired target ligands, pharmaceutical compositions comprising such peptides, and uses for such peptides. The modified WW domain peptides have altered, improved or different, target ligand binding characteristics to those of the unmodified WW domain peptides from which they are derived.
A naïve WW domain peptide library which has a consensus sequence derived from a WW domain peptide sequence which has been diversified by changing the amino acid sequence at one or more positions, and wherein the consensus sequence has at least three invariant tryptophan residues.
A modified WW domain peptide derived from a wild-type WW domain peptide sequence which has been diversified by changing the amino acid sequence at one or more positions, and wherein the modified WW domain peptide binds a target ligand not bound by the wild-type WW domain peptide from which it is derived, provided that no more than 50% of the amino acids of the wild-type sequence are changed.
(canceled)
(canceled)
30-33. (canceled)
35-43. (canceled)
Dependencies are inferred from the claim text.